Recruiting

Dupixent & UVB

Sponsor:

Psoriasis Treatment Center of Central New Jersey

Code:

NCT05285839

Conditions

Atopic Dermatitis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Dupixent

Study Details

Brief summary:

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

Conditions

Atopic Dermatitis

Study ID

NCT05285839

Start date

Apr 19, 2022

Status verified date

Mar, 2024

Completion date

Dec 15, 2024

Anticipated

Primary completion date

Dec 1, 2024

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Male or female adult ≥ 18 years of age;
  • Diagnosis of moderate to severe atopic dermatitis as defined at baseline by:

  • EASI score of 16 or greater,
  • IGA score of 3 or greater
  • BSA of 10% or greater,

Exclusion Criteria:

  • Subjects with previous exposure to dupilumab.
  • Known or suspected hypersensitivity to dupilumab or any of its excipients.
  • History of photosensitivity.

Study Design

Enrollment

40 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Dupixent and Narrowband UVB

Dupixent and Narrowband UVB

Interventions

Dupixent

dupilumab 300mg

Primary outcome measure

  • Investigators Global Assessment Score of score of 0 or 1 [ Time Frame: 12 weeks ]

Central Contacts and Locations

Central contacts

Elise Nelson

6094434500enelson@windsordermatology.com

Locations

Eczema Treatment Center of New Jersey

Recruiting

East Windsor, New Jersey, United States, 08520

Contacts

Elise Nelson

609-443-4500enelson@windsordermatology.com

Principal Investigator:

Jerry Bagel, MD

More Information

Sponsor

Psoriasis Treatment Center of Central New Jersey

Last update posted

Mar 15, 2024

Last verified

Mar, 2024

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Psoriasis Treatment Center of Central New Jersey on 2024-03-15.